MidAmerica Healthcare Venture Forum: Advisory Board Members

Conference Chairman

Peter Kleinhenz: Managing Director
CID Capital; Peter Kleinhenz is a Managing Director of CID Capital. He has been actively involved in technology-based businesses as an entrepreneur, consultant, and investor for over 20 years and leads CID's investments in life sciences. Prior to joining CID, Peter served as VP of Commercialization for Battelle Memorial Institute and as an independent consultant to The Cleveland Clinic Foundation, Battelle, and a variety of life science start-ups. Peter was CEO of Progenics, which he sold to Fitch, Inc., an international product design and development firm and served in a variety of senior executive positions at Neoprobe Corporation, a biotech device company focused on cancer diagnostics and therapeutics. Peter received an MBA from The Weatherhead School of Management at Case Western Reserve University, a BA degree in history from Loyola University of Chicago, and is a Certified Public Accountant, Ohio inactive license.

Advisory Board Members

George Arida: Managing Director
Venture Investors, LLC; George Arida is a Managing Director of Venture Investors LLC with a focus on the firm's healthcare practice. George currently serves as the Board Chair for Zystor Therapeutics, Inc. and Nerites Corporation, as Lead Director at ProCertus BioPharm, Inc., and as Director for Celleration, Inc. and Board Observer for Chromatin, Inc. He also serves on the Board of the Mid-America Healthcare Investors Network, an association of over forty regional venture capital firms active in early stage healthcare investing. George most recently served as the CFO for a financial consulting and brokerage firm. Prior to this, he spent five years at U.S. Filter Corporation in various management and marketing positions, four years with Betz Laboratories in technical sales and field service management, and two years at Alar Engineering as a Process Engineer. George has a Bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration degree with high honors from the University of Chicago.

Carrie Bates: Managing Partner
Triathlon Medical Ventures; Carrie Bates, Managing Partner of Triathlon Medical Ventures, has over 20 years of venture and operating experience, with a focus on medical devices and pharmaceuticals. She is Chairman of the Board of CS-Keys, on the Board of Directors of Mitralign and Pradama, and was on the Board of Directors of Remon Medical Technologies prior to its acquisition by Boston Scientific. At Guidant Corporation she ran Compass, Guidant’s venture group. Prior to that, she held various senior management operating positions at Guidant and Eli Lilly. She has an MBA from Stanford, a BS in Finance and a BS in Computer Science, and is a CPA.

Mike Brooks: President/CEO
Indiana Health Industry Forum (IHIF); Mike Brooks is the President and Chief Executive Officers of the Indiana Health Industry Forum. Brooks was appointed to head IHIF in July 2005. The not-for-profit, private sector organization, and its members represent a private and public alliance of manufacturers, suppliers, educational institutions, health care providers, service providers and government. Prior to IHIF, Brooks was associate vice president for research and economic development and director of Innovation Campus at Utah State University. While in that state, he was appointed to serve on the governor’s economic development advisory board and was a member of the Association of University Research Parks. He is a native of Greensburg, Indiana, Brooks received a B.A. from Purdue University where he studied sociology, and economics. He held leadership roles in the Kokomo/Howard County Chamber of Commerce, Mt. Vernon Chamber of Commerce and the Greater Bloomington Chamber of Commerce. Before heading to Utah in 2004, he spent fourteen years as President of the Lafayette-West Lafayette Economic Development Corporation. He also collaborated with Purdue to create the university's high tech incubator.

Brian Clevinger: Managing Director
Prolog Ventures; Brian Clevinger is a founder and managing director of Prolog. Brian has 20 years of experience in all phases of commercial technology development. He currently focuses on drug delivery, aesthetic materials and devices, and plant biotechnology. Previously, following an academic career in a tenured position at Washington University in St. Louis, he learned the art of investing at an affiliate of Alafi Capital and then served as founding CEO of a vaccine delivery company. Brian holds a doctorate in immunology from Indiana University and has completed his postdoctoral fellowship at Washington University.

Kevin Driscoll: Director, Global New Business & Technology Development
Procter & Gamble Health Care; Dr. Kevin Driscoll is the Director of Global New Business & Technology Development for Procter & Gamble Pharmaceuticals. He joined P&G in 1986 and has held numerous leadership positions across P&G businesses in Health and Beauty Care, most recently, serving as Director, Pharmaceuticals Discovery Research. In 2006, Dr. Driscoll was appointed to his current role in which he leads P&G Pharmaceuticals’ global efforts to find, evaluate and in-license new pharmaceutical compounds, devices and diagnostics. He also is responsible for the pharmaceutical development pipeline from preclinical through proof of concept. Outside of P&G, Dr. Driscoll has served in numerous advisory roles for the U.S. Environmental Protection Agency; Food & Drug Administration; World Health Organization; and, the National Research Council’s (NRC) Committee on Toxicology.

George Emont: Partner
Triathlon Medical Ventures; George Emont is a partner with Triathlon Medical Ventures and a Managing Partner of the Kentucky Seed Capital Fund. Mr. Emont’s more than two decades of health care industry experience include 13 years in venture capital. Prior to joining Triathlon and KCSF, Mr. Emont was Director of Venture Capital for Humana Inc. where he managed a venture capital fund that made investments totaling over $75 million in 11 portfolio companies and three venture funds. Mr. Emont’s resume includes service with Baxter Healthcare Corporation and IAI Venture Capital Group, followed by the successful launch and eventual sale of oncology-focused biotechnology start-up OncoTherapeutics. Mr. Emont currently is on the boars of Celleration, ApoImmune, RhinoCyte, AllTranz and OrthoData. Mr. Emont is from Granville, Ohio, holds a B.A. from Oberlin College in Oberlin, Ohio, and an M.B.A. from the University of Chicago.

Jan Garfinkle: Managing Director
Arboretum Ventures; Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering to select and nurture outstanding companies. Jan currently serves on the board of directors for HandyLab, VasoNova, Mirabilis Medica, and NXThera and as an observer for Uptake Medical, BAROnova and Esperion Therapeutics. Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions and was Founder and President of Strategic Marketing Consultants. Earlier in her career, Jan was part of the senior management team for two successful medical device start-up companies, advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI), both of which were acquired and became part of Guidant Corporation. Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Scott Glickson: Partner
McGuireWoods, LLP; Mr. Glickson advises life science, software, technology consulting, telecommunications, and other emerging and established technology companies in business organization, corporate finance, and commercial matters, including mergers, acquisitions, and divestitures. He is experienced in a wide range of debt and equity financings, including venture capital and other private placements, public offerings, and commercial lending. In November 1997, he was named by Crain's Chicago Business to its Technology 100 list, as one of the 100 most influential technology players in Chicago. He has been named by i-Street Magazine as one of the Top 100 people in Chicago's new economy.

Mike Jerstad: Partner
Prairie Gold Ventures; Mike Jerstad is a Partner at PrairieGold Venture Partners, an early stage venture capital firm focused on life science and cleantech opportunities in the Midwest. He oversees all aspects of the firm’s investment activities, from sourcing, structuring and negotiating investments to serving as a board member for portfolio companies. Mike focuses on life science opportunities, and represents PrairieGold on the boards of Chronix Biomedical, PetMedicus Labs and Orasi Medical. Prior to joining PrairieGold, Mike worked in Piper Jaffray's Investment Banking Group in its Minneapolis and San Francisco offices, specializing in merger and acquisition advisory services and public and private equity financing. Before Piper, Mike was an attorney at Briggs and Morgan in Minneapolis, specializing in business litigation, employment law and contracts. He received his B.A. from Tufts University, his J.D. from Georgetown University and his M.B.A. from the University of Chicago.

Ben Keeton: Executive Director
Kentucky BioAlliance; Ben Keeton is the co-founder and Executive Director of the Kentucky BioAlliance, an economic development group focused on Kentucky’s biotech sector. The Kentucky BioAlliance connects, promotes and develops the life science assets of the Commonwealth's thriving bioscience industry. As a catalyst for sharing ideas and exchanging knowledge, we are a community where industry leaders, entrepreneurs, investors, and educational institutions collaborate to turn science into success. In his role, Ben will work with industry leaders to develop a statewide alliance for life science business that will enable Kentucky to compete in life science economic development, which includes fields such as advanced medical device manufacturing, nanotechnology and pharmaceutical & biotechnology drug development.

Beverly Lyman: Partner & Life Sciences Partner
Thompson Hine; Dr. Lyman is a registered patent attorney and a partner in Thompson Hine's Intellectual Property and Life Sciences practice groups. A former faculty member at the medical campus of the University of Tennessee, she focuses her practice on chemical, medical, and life sciences patent evaluation, enforcement, transactions, and prosecution, as well as handling trademark, trade secret, and copyright matters. She is admitted to practice before the U.S. Patent and Trademark Office and in the States of Ohio and Georgia.

She holds an appointment as Adjunct Professor at the University of Cincinnati College of Law, where she has developed and teaches Licensing Intellectual Property. She also lectures on biotechnology patent prosecution for the Patent Resources Group (PRG). As an academic, she has authored numerous scientific publications, including chapters in clinical texts and a biochemistry study guide.

Dan Meek: Director Life Science Commercialization
TechColumbus; Dan Meek has 20 years of product development experience, including 12 years within the BioScience industry. Prior to TechColumbus, Dan was Senior Director of Product Development for Ventaira Pharmaceuticals, a privately held specialty pharmaceutical company in Columbus, Ohio. At Ventaira, Dan was part of the management team responsible for commercializing novel technology for respiratory drug delivery. His experience in drug product development includes market research and competitive analysis, pharmaceutical project management, medical device engineering, GMP manufacturing, pre-clinical, clinical and regulatory affairs. He has managed several early stage drug development projects for leading global pharmaceutical companies. Dan joined Ventaira after serving as principal engineer at Battelle Memorial Institute, where he managed an engineering team to develop a drug delivery device for the treatment of lung cancer. Dan received a Masters of Business Administration from Capital University in Columbus, Ohio. He holds a Bachelor of Science in Mechanical Engineering from Ohio Northern University.

Peter Shagory: Partner
Baird Venture Partners; Pete is a Partner with Baird Venture Partners and oversees the healthcare and life sciences investment effort. Prior to joining Baird Venture Partners in 2004, Pete spent five years at Vector Fund Management, a life-sciences venture capital firm, investing broadly across the medical device and biotechnology fields. Prior to Vector, he spent over six years in corporate finance, mergers & acquisitions and merchant banking at JP Morgan & Co. and Banc One Capital Corporation. Pete is currently Board Chairman of Accuri Cytometers, he's a Board Director of Arbor Surgical Technologies, Caden Biosciences, Inc. and PharMEDium Healthcare Corporation, a former Director of NimbleGen Systems, and he oversees BVP's current investments in Aptus Endosystems, and Celleration, Pete also serves on the Board of the Wisconsin Biotechnology and Medical Device Association. He received his undergraduate degree in Business Administration and Finance from Miami University in Oxford, Ohio, and his MBA from the Amos Tuck School at Dartmouth College.

Mina Patel Sooch, M.B.A.: Founder and Managing Director
Apjohn Ventures; Mina Sooch brings with her over fifteen years of pharmaceutical and healthcare experiences as an entrepreneur, strategy & finance advisor, and venture capitalist. Since 2000, she has helped co-found Apjohn Ventures, Apjohn Group, and several local start-ups. Mina has served on 8 portfolio company boards as a venture investor and serves on the boards of the Midwest Healthcare Investment Network and Michigan Venture Capital Association. Prior to 2000, Mina spent eight years as a global account manager at Monitor Group, a top tier global strategy consulting firm based in Boston, with her client base consisting of mid-cap and large-cap healthcare companies and multi-billion dollar private equity companies. With a focus on M&A, she has worked on over 30 deals including $7B Pharmacia & Upjohn merger in 1995. Mina was also a co-founder of Monitor's Corporate Finance practice in 1998. Mina received a MBA from Harvard Business School in 1993. She graduated summa cum laude and commencement speaker from Wayne State University in 1989 with a B.S. in Chemical Engineering.

Kathleen A Tune: Associate
Thomas McNerney Partners; Kathy joined Thomas, McNerney & Partners from Piper Jaffray, where she was a health care analyst focused on medical technology companies. While at Piper, Kathy covered over 20 companies in the medical device, medical supply and diagnostic areas. Her background also includes experience in new product development at Solvay, S.A. (in a division that is now part of Wyeth). Projects at Solvay included the development of vaccines for the prevention of viral infections. Kathy also was a Senior Scientist in molecular biology at the University of Minnesota, where she worked on the development of molecular biology based assays for the detection of infectious agents. Kathy is currently a board member of Softscope Medical Technologies, Inc. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.

David Wight: Executive Director
Edison Biotechnology Institute; David Wight is Director of Ohio University’s Edison Biotechnology Institute (EBI), a research unit focused on the development and commercialization of new biomedical technologies. He has over 20 years of professional experience in scientific research and has been involved in the generation, protection, and commercialization of university faculty technologies for the past 15 years, first as a scientist and for the past 13 years as director. Dr. Wight also serves as Director of BioOhio’s Southeastern Ohio regional office. In that role, Dr. Wight provides business assistance to regional bioscience companies and is actively engaged with regional economic development officials through membership on the Technology Development Committee of the Athens Area Chamber of Commerce Economic Development Commission. Dr. Wight received his undergraduate degree at the University of California, Santa Barbara and his graduate training at the University of Michigan. After a postdoctoral fellowship at Ohio University, he joined the scientific staff of EBI in 1988. He became director in 1995 and completed an MBA in 1997.

Host Committee Chair

Carol Frankenstein: President
BioStart; Carol J. Frankenstein is the President of BIOSTART, Cincinnati's bio/medical business start-up center and regional affiliate of BioOhio, Ohio’s life science industry association. With over 20 years experience in health care management, she has had a role in guiding 100 life science companies and over 300 entrepreneurs. Under her leadership, start-up clients have generated over $170 MM in grant, research contract and equity investments and created 180 jobs. She co-founded SoundingBoard^SM a regional business plan review program and Cincinnati Creates Companies, a regional business plan writing program for technology businesses. She has an MBA from the University of Chicago and a BA from Ohio State University. She serves on the Federal Reserve Bank Regional Business Advisory Board, and is the past chair of the Ohio’s Thomas Edison Incubator Director’s Council.

Host Committee Members

Dorothy Air, Ph.D.: Associate Senior Vice President for Entrepreneurial Affairs
University of Cincinnati; DOROTHY H. AIR, PhD, Associate Senior Vice President for Entrepreneurial Affairs at the University of Cincinnati, is responsible for developing networks and resources to support commercialization activities of UC. She manages a $1.65 million Pre-seed Fund from the ODOD Third Frontier Program and directs an NSF funded entrepreneurial training program. She serves on Boards of BIO/START, EMTEC, Hamilton County Business Center, Greater Cincinnati Venture Association and Cincinnati/Northern Kentucky Airport. She initiated the Ohio Valley Affiliates for Life Sciences, comprised of 5 Ohio and Kentucky universities, AFRL, and regional economic development groups to increase visibility for the research/commercialization capabilities of the region. She is a loaned executive to CincyTechUSA and part of the implementation team for the region’s Entrepreneur Signature Program. Recognitions include 2006 Women’s Business Cincinnati Top 10 Women in Technology and 2007 Leading Woman of Greater Cincinnati for Entrepreneurship.

Rick J. D'Augustine: CincyTech; Mr. D’Augustine has almost 30 years of medical industry experience in general management, venture capital investing and business development in both public and private companies. He is currently an Executive-in–Residence at CincyTech, a regional high technology venture development organization. Just prior to joining Cincytech, Mr. D’Augustine was President & CEO of UMD, Inc., a venture-backed drug delivery company focusing on women’s health issues.

Previously, Rick spent five years as a group director at Senmed Medical Ventures and sixteen years with Johnson & Johnson, where he was a founding board member of Ethicon Endo-Surgery. He has also served as a founder and director at several early stage medical technology companies, including, Atricure, Inc., which is now a public company.

Rick has a BSME from Rensselaer Polytechnic Institute and an MBA from Seton Hall University.

Anthony J. Dennis, Ph.D.: President & CEO
BioOhio; Anthony J. Dennis, Ph.D., an entrepreneur, microbiologist, technology advocate and native Ohioan, became president and Chairman of the Board to BioOhio, on January 1, 2002. He received his B.S. and Ph.D. Degrees in microbiology from The Ohio State University. He started his career at Battelle Memorial Institute in the 1980’s, first as an entry-level researcher and eventually as vice president for biotechnology. President and founder of IntraCel, a biotech company operating in Geneva, Switzerland, from 1988-1990. Vice President of Tastemaker, operating research and new product groups in the US, England, Japan and the Netherlands until 1997. Co-founder and President of Nutri-Logics, Inc. 1997-2000. Co-founder, Executive Vice President of BIO-NOVA in Portland, prior to joining BioOhio. A director of the Oregon Biotechnology Association (OBA), and consultant for the Oregon Resource and Technology Development Account.

Allen J. Dines: President
Midwest Research University Network
Asst. Director, Office of Corporate Relations University of Wisconsin-Madison; Mr. Dines is Assistant Director of the UW-Madison Office of Corporate Relations (OCR). He is involved in all aspects of OCR operations including, outreach to business and industry, promoting local and regional economic growth through technology transfer of UW-Madison research and maintaining and building local, regional and national cooperative relationships for UW-Madison. Mr. Dines joined the UW Madison in 2001 bringing over 25 years of experience in industry and technology management. He also severed as Assistant Director for Business Development, within the Graduate School where his major focus was commercialization of university technology through startup business development and campus entrepreneurship. In 2002, Mr. Dines co-founded the Midwest Research University Network, bringing research institutions in the Midwest together for regional cooperation in the commercialization of university research through new business creation. Mr. Dines serves on advisory boards of several Madison area business acceleration enterprises, the UW Entrepreneurship Association and the UW chapter of AIESEC. Previously, he served as president and CEO of MitoScan Corporation, a startup Madison biosensor company; and BioRenewal, an environmental biotechnology company. Mr. Dines was named a Wisconsin Idea Fellow in 2004 by the president of the UW System. He holds degrees from the University of Michigan including a B.S, a Master of Business Administration, and a Master of Regional Planning in Natural Resources.

Carter McNabb: River Cities Fund; Carter manages the healthcare practice at River Cities where he focuses on investments in healthcare services, medical devices and healthcare information technology. He joined River Cities in 1999 after completing his MBA in Finance at the Owen School at Vanderbilt University. While a graduate student at Vanderbilt, he was selected as Bradford Fellow to conduct equity research activities for J.C.Bradford & Co., a leading regional investment bank now part of UBS. Prior to business school, he worked in the marketing and development department of a start-up, venture-backed healthcare services organization acquired by Integrated Health Services, Inc. Carter graduated from Trinity College (CT) where he received his BA in Classical Greek and Latin Studies. Carter serves on the board of Health Integrated, Inspiris, AcceleCare Wound Centers, PerfectServe and OrthoHelix Surgical Designs.

Karen E. Morgan, M.B.A.: Director
Charter Life Sciences; Karen has over 15 years of venture capital experience at two venture capital funds investing in devices, diagnostics, healthcare services, and biotech/specialty pharmaceutical deals. Currently at Charter Life Sciences, she is responsible for co-managing the Cincinnati office. Additionally, Ms. Morgan acts as an independent consultant assisting healthcare start-up companies and is the current interim CFO of Akebia Therapeutics. Prior to joining CLS, Karen was a partner with Senmed Medical Ventures, where she was responsible for financial management of Senmed's more than $100 million venture capital and technology licensing portfolio. She served as a member of the Investment Committee and was also responsible for all legal transactions closing over 50 private placement transactions and several licensing deals. Karen represented Senmed on several boards of directors and she served as CFO of five start-up companies. Prior to Senmed, Karen held various positions in small and medium sized companies in the telecommunications industry. She started her career at the U.S. Securities and Exchange Commission. Ms. Morgan holds an MBA from American University and a BA with honors in economics and business from Catholic University.

Caralynn Nowinski, M.D.: Associate
Midwest Venture Partners; Dr. Nowinski is an Associate with Midwest Venture Partners and ARCH Development Partners, where she takes an active role in due diligence, financial modeling/valuation and monitoring of current portfolio companies. As a joint MD/MBA student at the University of Illinois at Chicago, she co-founded SanoGene Therapeutics, an early-stage biotech company, and she currently serves as its President and Acting CEO. Prior to medical school, Dr. Nowinski managed two NIH-funded clinical research programs, authoring several peer-reviewed scientific articles in the neurosciences. She graduated with honors (B.S.) from Northwestern University.